{"count": 30, "results": [{"_id": "37866351", "pmid": 37866351, "pmcid": "PMC10652658", "title": "Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus", "journal": "Kidney Blood Press Res", "authors": ["Seki Y", "Morimoto S", "Kimura S", "Takano N", "Yamashita K", "Bokuda K", "Sasaki N", "Watanabe D", "Ichihara A"], "date": "2023-10-20T00:00:00Z", "doi": "10.1159/000533834", "meta_date_publication": "2023 Oct 20", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50252.05, "text_hl": "Effects of @CHEMICAL_aliskiren @CHEMICAL_MESH:C446481 @@@Aliskiren@@@ Monotherapy versus @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@ Monotherapy in Hypertensive @SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@Obesity@@@ or @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@Type 2 Diabetes Mellitus@@@", "citations": {"NLM": "Seki Y, Morimoto S, Kimura S, Takano N, Yamashita K, Bokuda K, Sasaki N, Watanabe D, Ichihara A. Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus Kidney Blood Press Res. 2023 Oct 20;():. PMID: 37866351", "BibTeX": "@article{37866351, title={Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus}, author={Seki Y and Morimoto S and Kimura S and Takano N and Yamashita K and Bokuda K and Sasaki N and Watanabe D and Ichihara A}, journal={Kidney Blood Press Res}}"}}, {"_id": "27051525", "pmid": 27051525, "pmcid": "PMC4820991", "title": "Changes of blood pressure, abdominal visceral fat tissue and gene expressions in fetal programming induced rat model after amlodipine-losartan combination treatment", "journal": "Clin Hypertens", "authors": ["Lee JH", "Lee H", "Lee SM", "Kang PJ", "Kim KC", "Hong YM"], "date": "2016-04-05T00:00:00Z", "doi": "10.1186/s40885-016-0046-9", "meta_date_publication": "2016", "meta_volume": "22", "meta_issue": "", "meta_pages": "12", "score": 50070.94, "text_hl": "@<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@-@CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ combination treatment reduced @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obesity@@@, @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, @DISEASE_Hypertriglyceridemia @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@ and the changes in genes.", "citations": {"NLM": "Lee JH, Lee H, Lee SM, Kang PJ, Kim KC, Hong YM. Changes of blood pressure, abdominal visceral fat tissue and gene expressions in fetal programming induced rat model after amlodipine-losartan combination treatment Clin Hypertens. 2016;22():12. PMID: 27051525", "BibTeX": "@article{27051525, title={Changes of blood pressure, abdominal visceral fat tissue and gene expressions in fetal programming induced rat model after amlodipine-losartan combination treatment}, author={Lee JH and Lee H and Lee SM and Kang PJ and Kim KC and Hong YM}, journal={Clin Hypertens}, volume={22}, pages={12}}"}}, {"_id": "21925996", "pmid": 21925996, "title": "Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome.", "journal": "J Am Soc Hypertens", "authors": ["Weinberger MH", "Izzo JL Jr", "Purkayastha D", "Weitzman R", "Black HR"], "date": "2011-11-01T00:00:00Z", "doi": "10.1016/j.jash.2011.08.005", "meta_date_publication": "2011 Nov-Dec", "meta_volume": "5", "meta_issue": "6", "meta_pages": "489-97", "score": 50060.887, "text_hl": "Comparative efficacy and safety of combination @CHEMICAL_aliskiren @CHEMICAL_MESH:C446481 @@@aliskiren@@@/@<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ monotherapy in African Americans with stage 2 @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obesity@@@ or @DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@metabolic syndrome@@@.", "citations": {"NLM": "Weinberger MH, Izzo JL Jr, Purkayastha D, Weitzman R, Black HR. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. J Am Soc Hypertens. 2011 Nov-Dec;5(6):489-97. PMID: 21925996", "BibTeX": "@article{21925996, title={Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome.}, author={Weinberger MH and Izzo JL Jr and Purkayastha D and Weitzman R and Black HR}, journal={J Am Soc Hypertens}, volume={5}, number={6}, pages={489-97}}"}}, {"_id": "23889722", "pmid": 23889722, "pmcid": "PMC3908371", "title": "Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis", "journal": "J Clin Hypertens (Greenwich)", "authors": ["Roth EM", "Oparil S", "Melino M", "Lee J", "Fernandez V", "Heyrman R"], "date": "2013-08-01T00:00:00Z", "doi": "10.1111/jch.12133", "meta_date_publication": "2013 Aug", "meta_volume": "15", "meta_issue": "8", "meta_pages": "584-92", "score": 50060.34, "text_hl": "The objective of this prespecified TRINITY study subgroup analysis was to assess the efficacy and safety of triple-combination treatment with @CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@olmesartan medoxomil@@@ (@CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@OM@@@) 40 mg, @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine besylate@@@ (@<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@AML@@@) 10 mg, and @CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@hydrochlorothiazide@@@ (@CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@HCTZ@@@) 25 mg vs the component dual-combination treatments in @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obese@@@ (body mass index [BMI] >=30 kg/m2) and nonobese (BMI <30 kg/m2) @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ participants. ", "citations": {"NLM": "Roth EM, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis J Clin Hypertens (Greenwich). 2013 Aug;15(8):584-92. PMID: 23889722", "BibTeX": "@article{23889722, title={Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis}, author={Roth EM and Oparil S and Melino M and Lee J and Fernandez V and Heyrman R}, journal={J Clin Hypertens (Greenwich)}, volume={15}, number={8}, pages={584-92}}"}}, {"_id": "23573487", "pmid": 23573487, "pmcid": "PMC3614294", "title": "The Impact of Amlodipine on Gingival Enlargement After Kidney Transplantation", "journal": "Nephrourol Mon", "authors": ["Rostami Z", "Einollahi B", "Einollahi MJ", "Lessan S"], "date": "2012-07-01T00:00:00Z", "doi": "10.5812/numonthly.5427", "meta_date_publication": "2012 Summer", "meta_volume": "4", "meta_issue": "3", "meta_pages": "565-70", "score": 50059.75, "text_hl": "In logistic regression analysis, @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obese@@@ (OR = 3, P = 0.04), older (OR = 2.8, P = 0.03), and female (OR = 1.3, P = 0.03) recipients as well as who received high dose @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ (OR = 4.4, P = 0.000) were at risk for marked @DISEASE_Gingivitis @DISEASE_MESH:D005891 @@@GE@@@.", "citations": {"NLM": "Rostami Z, Einollahi B, Einollahi MJ, Lessan S. The Impact of Amlodipine on Gingival Enlargement After Kidney Transplantation Nephrourol Mon. 2012 Summer;4(3):565-70. PMID: 23573487", "BibTeX": "@article{23573487, title={The Impact of Amlodipine on Gingival Enlargement After Kidney Transplantation}, author={Rostami Z and Einollahi B and Einollahi MJ and Lessan S}, journal={Nephrourol Mon}, volume={4}, number={3}, pages={565-70}}"}}, {"_id": "23148200", "pmid": 23148200, "title": "Antihypertensive treatment in patients with class 3 obesity.", "journal": "Ther Adv Endocrinol Metab", "authors": ["Jordan J", "Boye SW", "Breton SL", "Keefe DL", "Engeli S", "Prescott MF"], "date": "2012-06-01T00:00:00Z", "doi": "10.1177/2042018812445573", "meta_date_publication": "2012 Jun", "meta_volume": "3", "meta_issue": "3", "meta_pages": "93-8", "score": 50058.785, "text_hl": "While addition of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@, @CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@irbesartan@@@, or @CHEMICAL_aliskiren @CHEMICAL_MESH:C446481 @@@aliskiren@@@ to @CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@hydrochlorothiazide@@@ improved the blood pressure response, @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ was less effective and induced @DISEASE_Edema @DISEASE_MESH:D004487 @@@peripheral edema@@@ in 19% of @SPECIES_9606 @@@patients@@@ with class 3 @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obesity@@@.", "citations": {"NLM": "Jordan J, Boye SW, Breton SL, Keefe DL, Engeli S, Prescott MF. Antihypertensive treatment in patients with class 3 obesity. Ther Adv Endocrinol Metab. 2012 Jun;3(3):93-8. PMID: 23148200", "BibTeX": "@article{23148200, title={Antihypertensive treatment in patients with class 3 obesity.}, author={Jordan J and Boye SW and Breton SL and Keefe DL and Engeli S and Prescott MF}, journal={Ther Adv Endocrinol Metab}, volume={3}, number={3}, pages={93-8}}"}}, {"_id": "23072496", "pmid": 23072496, "title": "Efficacy of amlodipine/olmesartan medoxomil +- HCTZ in obese patients uncontrolled on antihypertensive monotherapy.", "journal": "Curr Med Res Opin", "authors": ["Hsueh WA", "Shojaee A", "Maa JF", "Neutel JM"], "date": "2012-11-01T00:00:00Z", "doi": "10.1185/03007995.2012.740632", "meta_date_publication": "2012 Nov", "meta_volume": "28", "meta_issue": "11", "meta_pages": "1809-18", "score": 50057.848, "text_hl": "RESEARCH DESIGN AND METHODS: Eligible @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obese@@@ (body mass index >=30 kg/m(2); n = 505) and non-@<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obese@@@ (<30 kg/m(2); n = 494) @SPECIES_9606 @@@patients@@@ were switched to @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@AML@@@/@CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@OM@@@ 5/20 mg and uptitrated at 4-week intervals to @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@AML@@@/@CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@OM@@@ 5/40 mg, @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@AML@@@/@CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@OM@@@ 10/40 mg, @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@AML@@@/@CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@OM@@@ 10/40 mg + @CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@HCTZ@@@ 12.5 mg, and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@AML@@@/@CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@OM@@@ 10/40 mg + @CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@HCTZ@@@ 25 mg. ", "citations": {"NLM": "Hsueh WA, Shojaee A, Maa JF, Neutel JM. Efficacy of amlodipine/olmesartan medoxomil +- HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Curr Med Res Opin. 2012 Nov;28(11):1809-18. PMID: 23072496", "BibTeX": "@article{23072496, title={Efficacy of amlodipine/olmesartan medoxomil +- HCTZ in obese patients uncontrolled on antihypertensive monotherapy.}, author={Hsueh WA and Shojaee A and Maa JF and Neutel JM}, journal={Curr Med Res Opin}, volume={28}, number={11}, pages={1809-18}}"}}, {"_id": "27536431", "pmid": 27536431, "pmcid": "PMC4937657", "title": "Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index", "journal": "J Drug Assess", "authors": ["Axthelm C", "Sieder C", "Meister F", "Pittrow D", "Kaiser E"], "date": "2012-12-25T00:00:00Z", "doi": "10.3109/21556660.2012.762367", "meta_date_publication": "2013", "meta_volume": "2", "meta_issue": "1", "meta_pages": "1-10", "score": 50057.375, "text_hl": "Weinberger et al. reported that the @CHEMICAL_aliskiren @CHEMICAL_MESH:C446481 @@@aliskiren@@@/@<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ combination was more effective than @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ monotherapy in African-Americans with @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obesity@@@ or @DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@metabolic syndrome@@@. ", "citations": {"NLM": "Axthelm C, Sieder C, Meister F, Pittrow D, Kaiser E. Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index J Drug Assess. 2013;2(1):1-10. PMID: 27536431", "BibTeX": "@article{27536431, title={Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index}, author={Axthelm C and Sieder C and Meister F and Pittrow D and Kaiser E}, journal={J Drug Assess}, volume={2}, number={1}, pages={1-10}}"}}, {"_id": "21649842", "pmid": 21649842, "title": "Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.", "journal": "J Clin Hypertens (Greenwich)", "authors": ["Punzi H", "Shojaee A", "Waverczak WF", "Maa JF"], "date": "2011-06-01T00:00:00Z", "doi": "10.1111/j.1751-7176.2010.00422.x", "meta_date_publication": "2011 Jun", "meta_volume": "13", "meta_issue": "6", "meta_pages": "422-30", "score": 50057.043, "text_hl": "Efficacy of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and @CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@olmesartan medoxomil@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ and @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@obesity@@@.", "citations": {"NLM": "Punzi H, Shojaee A, Waverczak WF, Maa JF. Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. J Clin Hypertens (Greenwich). 2011 Jun;13(6):422-30. PMID: 21649842", "BibTeX": "@article{21649842, title={Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.}, author={Punzi H and Shojaee A and Waverczak WF and Maa JF}, journal={J Clin Hypertens (Greenwich)}, volume={13}, number={6}, pages={422-30}}"}}, {"_id": "7936332", "pmid": 7936332, "title": "[The effect on left ventricular mass of treatment with amlodipine and diet therapy in obese patients with arterial hypertension].", "journal": "Minerva Cardioangiol", "authors": ["Ruvolo G", "Greco E", "Speziale G", "Di Natale M", "Marino B"], "date": "1994-06-01T00:00:00Z", "meta_date_publication": "1994 Jun", "meta_volume": "42", "meta_issue": "6", "meta_pages": "289-92", "score": 50057.043, "text_hl": "From February to July 1993 32 @<m>DISEASE_Obesity</m> @DISEASE_MESH:D009765 @@@hypertensive obese@@@ @SPECIES_9606 @@@patients@@@ (17 males, 15 females) were treated with @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ 10 mg/day for six months. ", "citations": {"NLM": "Ruvolo G, Greco E, Speziale G, Di Natale M, Marino B. [The effect on left ventricular mass of treatment with amlodipine and diet therapy in obese patients with arterial hypertension]. Minerva Cardioangiol. 1994 Jun;42(6):289-92. PMID: 7936332", "BibTeX": "@article{7936332, title={[The effect on left ventricular mass of treatment with amlodipine and diet therapy in obese patients with arterial hypertension].}, author={Ruvolo G and Greco E and Speziale G and Di Natale M and Marino B}, journal={Minerva Cardioangiol}, volume={42}, number={6}, pages={289-92}}"}}]}